Clinical Trials Logo

Chronic Lymphoid Leukemia clinical trials

View clinical trials related to Chronic Lymphoid Leukemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04883749 Active, not recruiting - Clinical trials for Chronic Lymphoid Leukemia

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

CLL-Frail
Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The aim of this trial is to show the efficacy, safety and feasibility of acalabrutinib in a cohort of CLL-patients ≥80 years or with a FRAIL scale score >2 (5-item questionnaire to be filled out by the patient)

NCT ID: NCT04608318 Active, not recruiting - Clinical trials for Chronic Lymphoid Leukemia

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

CLL17
Start date: March 1, 2021
Phase: Phase 3
Study type: Interventional

The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.

NCT ID: NCT04515238 Active, not recruiting - Clinical trials for Chronic Lymphoid Leukemia

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

CLL2-BZAG
Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

CLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.

NCT ID: NCT00788684 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Start date: July 21, 2009
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active participants to continue to receive ABT-263 for up to 13 years after the last participant transitions with quarterly study evaluations.